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Immune checkpoint inhibitor (ICI) therapy has demonstrated impressive antitumor 
activity.1 However, it causes adverse effects, including lichenoid reactions.1,2 Cases of 
ICI-triggered bullous pemphigoid (BP) and anecdotally mucous membrane pemphigoid 
(MMP) have also been reported. 2-6 We describe two new cases of pembrolizumab-
triggered MMP, one of which was associated with cutaneous lichenoid lesions. 
Case 1. A 77-year-old man presented with metastatic melanoma for which he received 
pembrolizumab and stereotactic radiation therapy (Table 1). Six months later he 
developed pruritic skin lesions followed by painful oral lesions. Examination revealed 
lichenoid papules on the limbs as well as oral erosions of the cheek mucosa and gingiva 
(Fig. 1). Light microscopy studies of skin and mucosal biopsy specimens showed a 
lichenoid inflammation with apoptotic basal keratinocytes and subepithelial cleft formation 
with eosinophils, respectively. Immunopathological studies confirmed the diagnosis of A
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MMP. The patient was given doxycycline and topical corticosteroids with partial remission 
of oral lesions, while the lichenoid lesions resolved. Five-month after ICI cessation, his 
condition remained unchanged.
Case 2. An 81-year-old woman was given pembrolizumab for metastatic melanoma. 
Six months later, she presented with painful oral lesions of the buccal and gingival 
mucosa as well as isolated erosions on her face and scalp (Fig. 1). Light microscopy 
studies of a buccal mucosa were consistent with MMP. Immunopathological studies were 
positive (Table 1). The patient was given doxycycline and topical corticosteroids. During 
the 12-month follow up, despite ICI termination, she still had relapsing oral lesions, while 
skin lesions resolved.  
 MMP is an autoimmune subepithelial blistering disorder characterized by involvement 
of mucosal surfaces, a tendency for scarring and a variable reactivity profile of patients’ 
autoantibodies.3  Skin lesions, which are found in 25% of cases, are often limited and 
confined to the face and scalp, as in our second patient.3 Only three cases of MMP linked 
to ICI therapy have been described so far: while two cases had only mild oral 
involvement as in our two observations, the third case developed severe stenosis of the 
larynx. 4-6 Our first case was striking, since he developed oral MMP in combination with 
lichenoid cutaneous lesions. Lichenoid reactions with rarely mucosal involvement are 
observed in approximately 25% of cases during ICI therapy, but BP has also been 
increasingly reported. 2,5 In a review of 27 ICB-triggered BP cases, the median age was 
68 years.2,5   The interval between start of ICIs and BP onset was highly variable with a 
median of 6 months, as in our cases. The disease may however also occur several 
months after ICB discontinuation.5    
ICI therapy with anti-programmed death-1/ programmed death-ligand 1 results in a 
breakdown of tolerance, reduces activity of regulatory T cells (Tregs), and activates B 
cells and autoreactive T cells.1 Murphy mice characterized by a Tregs dysfunction 
develop both a lichenoid interface dermatitis and an autoantibody response to BP180 and 
BP230.7 Hence, Tregs blockade may result in both autoreactive cellular and humoral 
response to the same antigenic targets of the epidermal and epithelial BMZ. Lichen 
planus (LP) patients have also been found to have an autoreactive T cells against 
BP180, the major target antigen of BP and MMP.3,8 These findings may explain the A
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phenotype observed in our first patient showing concomitantly a cutaneous lichenoid and 
an oral subepithelial blistering dermatosis and further raise the question about the 
nosologic relationship of our first case with lichen planus pemphigoides as well as a new 
subtype of MMP with oral lichen features. 3,9 Hence, autoimmune blistering and lichenoid 
dermatoses, as also observed in in paraneoplastic pemphigus, seem to share an immune 
response directed against the same target antigens, explaining their potential clinical 
presentations overlap.10 The factors responsible for the final clinical phenotypes remains 
to be elucidated.
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Abbreviations:
ICB, immune checkpoint blockade
BP, bullous pemphigoid
MMP, mucous membrane pemphigoid
BMZ, basement membrane zone
CR, complete remission
PR, partial remission
Tregs, regulatory T cells
DIF, direct immunofluorescence microscopy
IIF, indirect immunofluorescence using NaCl-separated normal human skin
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Legend
Figure 1. Clinicopathological features of the patients. Case 1 with (a) isolated violaceus 
colored lichenoid maculopapular lesions on the upper limbs. (b)  Light microscopy studies 
of a skin biopsy specimen show an interface dermatitis, apoptotic keratinocytes and a 
lymphocytic infiltrate in the upper dermis with some eosinophils. (c) Erythema and 
erosions of the gingival margins. (d)  Light microscopy studies of an oral biopsy specimen 
demonstrate subepithelial blister formation and inflammation with eosinophils. (e) Direct 
immunofluorescence microscopy shows linear IgG deposits along the epithelial basement 
membrane zone. Case 2 (f) with desquamative gingivitis with edema, erythema and 
erosions. Sloughing of the mucosa with shaggy margins. 
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Table 1. Demographics and characteristics of reported cases of mucous membrane pemphigoid (MMP) after immune checkpoint inhibitor (ICI) therapy 
     
 
Patients 
Age, sex 
(reference) 
 
 
Malignancy 
 
Clinical features 
 
 
Immunopathology 
 
Management of  
malignancy 
   
 
Onset of MMP 
after starting ICI   
 
 
Therapy and  
course of MMP 
 
62 year, 
male 
(4) 
 
 
Metastatic 
Merkel cell 
carcinoma 
 
 
Oral blisters and 
erosions (tongue, 
buccal mucosa)   
No skin involvement 
 
 
Linear deposits of C3 along 
the epithelial BMZ  
ELISA-BP180, 23.6 U/mL 
IIF, epidermal staining   
IB, positive for BP180 (IgG, 
IgA) 
 
 
Pembrolizumab,  
(Keytruda®),  
2 mg/kg, every 3 
weeks  
 
 
13 weeks after 
initiation 
ICI then stopped 
 
 
   
Oral doxycyline 
Topical steroids  
PR on therapy 
 
83 years, 
Female 
(5) 
 
 
 
Metastatic 
melanoma 
 
Oral erosions, 
gingivitis,pseudo-
lichenoid lesions 
No skin involvement 
 
 
Linear deposits of IgG and C3 
along the epithelial BMZ 
IIF studies, negative 
ELISA-BP180, negative 
ELISA-BP230, negative 
IIE, positive 
 
Pembrolizumab  
2 mg/kg, every 3 
weeks   
 
 
  
 
 66 weeks   
(24 weeks after ICI 
stop) 
 
Oral doxycyline 
Corticosteroid oral 
washes 
CR off therapy after three 
months 
 
 
61 years, 
female 
(6) 
 
 
 
Metastatic  
ovarian 
adenocarcinoma  
 
Oral erosions and 
gingivitis 
Conjunctivitis, 
dysphagia, nasal and 
pharyngeal erosions, 
and laryngeal 
stenosis 
 
 
Linear deposits of IgG and C3 
along the epithelial BMZ 
IIF, epidermal staining   
 
 
 
Carboplatin and 
Paclitaxel, then  
Pembrolizumab  
2 mg/kg. stopped 
after 5 cycles (tumor 
progression) 
Start of doxorubicin 
 
 
6 weeks after ICI 
initiation  
  
  
 
 
Oral prednisone 
Infliximab 
Methylprednisolone 
IVIG 
Rituximab 
PR on therapy  
Death due to sepsis 
 
78 years, 
male 
 
Case 1 
Present 
report 
 
 
 
Malignant 
melanoma with 
brain and 
pulmonary  
metastases 
 
Pruritic cutaneous 
lichenoid lesions  
Oral cheek erosions, 
desquamative 
gingivitis 
 
 
Linear deposits of IgG along 
the epithelial and epidermal 
BMZ  
(with n-serration pattern) 
ELISA-BP180, 18.3 U/ml 
IIF, epidermal staining 
 
 
Stereotactic 
radiation and 
pembrolizumab, 
2 mg/kg, every 3    
for 38 cycles 
ICI stopped after 
CR of melanoma 
 
24 weeks after 
initiation 
 
 
Oral doxycyline 
Oral nicotinamide 
Topical corticosteroids 
PR on minimal therapy 
 
  
82 years, 
female 
 
Case 2 
Present 
report 
 
 
Malignant 
melanoma with 
skin metastases 
 
Oral blisters erosions 
of cheek mucosa, 
soft palate and 
desquamative 
gingivitis 
Single cutaneous 
blisters  
  
 
Linear deposits of IgG /C3 
along the epithelial and 
epidermal BMZ (with n-
serration pattern) 
ELISA-BP180, negative 
ELISA-BP230, negative 
 
 
 
Pembrolizumab 
3 weeks, for 16 
cycles 
ICI stopped after 
CR of melanoma 
 
 
24 weeks after 
initiation   
 
 
Oral doxycyline 
Corticosteroids oral 
washes 
Topical corticosteroids 
PR on minimal therapy 
 
BMZ, basement membrane zone; IIF, indirect immunofluorescence microscopy using NaCl-separated normal human skin; IIE, immunoelectron microscopy; CR and PR, complete response 
and partial response, respectively, according to either revised RECIST criteria or outcome measures for MMP; IVIG, intravenous immunoglobulins 
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